1.Preoperative evaluation of colorectal cancer with whole abdominal enhanced CT scan
Fengli CHEN ; Fene HAO ; Yinglong HUANG
Journal of Regional Anatomy and Operative Surgery 2016;25(9):640-643
Objective To evaluate the accuracy of enhanced CT scan in clinical staging of colorectal cance by detecting the general sit-uation and T and N staging through plain scan combined with enhanced CT scan.Methods Totally 49 cases of colorectal cancer patients were enrolled in this study from May 2015 to October 2015,and it showed no distant metastasis of colorectal cancer in clinical examination. Evaluated the general situation (location,size,and pathologic type)and T and N staging of colorectal cancer through plain scan and enhanced CT scan and multiplanar restructuring.Compared the imaging staging with pathological staging,and respectively calculated the sensitivity,spe-cific degree and accuracy of T and N staging.Evaluated the accuracy of T and N staging with the consistency test,and the differences were statistically significant with P <0.05.Results The location and pathological type of tumor detected by CT scan were compared with the re-sults of operation,and the coincidence rate was 100%.The maximum diameter of the tumor was (2.26 ±1.40)cm from CT image and (2.37 ±1.38)cm from operation measure,and the data were highly correlated (r =0.906,P =0.000).The coincidence rate of T staging was 65.3%,and the consistency was good (k =0.467,P =0.000).The coincidence rate of N staging was 63.3%,and the consistency was good (k =0.440,P =0.000).Conclusion Enhanced CT scan can provide sufficient information for the preoperative evaluation of colorectal cancer,and it has important clinical application value.
2.A clinical study on cerebral edema of intra-arterial thrombolytic recanalization in acute ischemic stroke
Hai MA ; Yajing REN ; Xiduo ZHANG ; Jing LIU ; Fengli HAO
Chongqing Medicine 2013;(28):3360-3362
Objective To observe the cerebral edema occurrence ,evolution and prognosis of intra-arterial thrombolytic recanali-zation in patients with acute ischemic stroke .Methods From October 2010 to October 2012 ,36 patients who underwent the intra-arterial thrombolytic therapy were cerebral recanalization .They were randomly divided into two groups :1-3 h group and >3-6 h group .The alteration of brain edema was observed by cranial CT .Their mRS .NHISS and BI were scaled and recorded before and after intra-arterial thrombolytic therapy .Results After intra-arterial thrombolytic therapy ,the occurrence rate of cerebral edema was 94% ,appeared at the onset of more than 1 hours in all patients .Long-term follow-up showed ,cerebral edema location appeared obvious cerebromalacia .Cerebral edema and clinical outcome had not significant difference between 1-3 h group and 3-6 h group . Conclusion Cerebral edema and loss of cerebral tissue occurred almost inevitability in patients who received intra-artery thromboly-sis and recanalized their cerebral artery .It indicates that good local circulation and general condition may be favorable factors that can gradually reduce brain edema .
3.Expression and clinical significance of forkhead transcription factor O1 in diffuse large B-cell lymphoma
Fengli YU ; Jun YUAN ; Jie YANG ; Jie LI ; Ruicang WANG ; Yan LI ; Hongling HAO
Journal of Leukemia & Lymphoma 2021;30(7):389-394
Objective:To investigate the correlation of the expression of forkhead transcription factor O1 (FOXO1) with clinicopathological features and the prognosis in patients with diffuse large B-cell lymphoma (DLBCL).Methods:The data of 42 patients newly diagnosed with DLBCL in Hebei General Hospital admitted from June 2012 to January 2020 were collected. The expressions of FOXO1, phosphorylated FOXO1 (p-FOXO1) in DLBCL tissues were detected by using immunohistochemistry. The association of FOXO1 expression with clinicopathological features and the prognosis in DLBCL patients was retrospectively analyzed.Results:The positive rate of FOXO1 was 42.9% (18/42) and the positive rate of p-FOXO1 was 28.6% (12/42) in DLBCL tissues. There were no statistically significant differences in the positive rates of FOXO1 and p-FOXO1 among patients stratified by gender, age, Ann Arbor staging, immunophenotype, Eastern Cooperative Oncology Group score, lactate dehydrogenase, international prognostic index, β 2-microglobulin (β 2-MG) and primary sites (all P > 0.05). The positive rate of FOXO1 in patients with non-B symptoms was higher than that in those with B symptoms [53.6% (15/28) vs. 21.4% (3/14), χ2=3.938, P=0.047], and there was no statistically significant difference in the positive rate of p-FOXO1 among patients with or without B symptoms ( P > 0.05). The 2-year overall survival (OS) rate in FOXO1 positive group was higher than that in FOXO1 negative group (90.9% vs. 66.7%), the 2-year OS rate in p-FOXO1 positive group was lower than that in p-FOXO1 negative group (50.0% vs. 85.0%), and the differences were not statistically significant (all P > 0.05). Among patients without B symptoms, the 2-year OS rate in FOXO1 positive group was higher than that in FOXO1 negative group (100.0% vs. 50.0%, χ2=5.486, P=0.019). Among patients with primary lymph node, elevated β 2-MG and non-B symptoms, the 2-year OS rate in p-FOXO1 negative expression group was higher than that in p-FOXO1 positive group (100.0% vs. 50.0%, 100.0% vs. 25.0%, 91.7% vs. 33.3%), and the differences were statistically significant (all P < 0.05). Conclusions:FOXO1 may be involved in the development and progression of DLBCL, and FOXO1 positive expression may indicate the good prognosis of patients. These results suggest that p-FOXO1 positive expression may be related with poor prognosis.
4.Nocardia cyriacigeorgica infection:one case report
Yunyun YANG ; Jiao LI ; Hao FU ; Fengli GUO ; Xiaofang YANG ; Wencong LI ; Youquan ZHOU
Chinese Journal of Infection and Chemotherapy 2018;18(6):646-648
5.Clinical and electrophysiological study of propriospinal myoclonus
Junyan ZHANG ; Bi WANG ; Xiaoli WANG ; Lang JIN ; Mingming WANG ; Li CHEN ; Fengli HAO ; Yonghong LIU
Chinese Journal of Neurology 2020;53(6):410-415
Objective:To discuss the clinical and electrophysiological characteristics of propriospinal myoclonus (PSM).Methods:The clinical and electrophysiological characteristics of four patients diagnosed as PSM in the Electroencephalography Monitoring Center, Department of Neurology, Xijing Hospital, the Air Force Military Medical University from April 2018 to July 2019 were studied. All patients were accorded with diagnostic criteria of PSM that international classification of sleep disorders-3 edition recommended and were followed up.Results:There were three males and one female in the four patients. The age of onset was ranged from 43 to 55 years. The course was from eight months to three years, and the follow-up time was from three months to one year. The clinical features of the four patients were characteristically paroxysmal tic or shaking of the neck, trunk or limbs, with short duration and great frequency. All patients accepted 24-hour video electroencephalography monitoring. No epileptic discharge was recorded during the monitoring. The burst activity of deltoid, quadriceps or rectus abdominis muscle was monitored by surface electromyography at the onset of myoclonus. All patients were treated with clonazepam. Three patients had an obvious curative effect and one patient had no effect.Conclusions:The clinical manifestation of PSM is similar to seizures. There is no epileptic discharge, and only the burst activity of muscles is monitored at the onset. Most patients have significant effect on clonazepam.
6.Targeting histone deacetylases for cancer therapy: Trends and challenges.
Tao LIANG ; Fengli WANG ; Reham M ELHASSAN ; Yongmei CHENG ; Xiaolei TANG ; Wengang CHEN ; Hao FANG ; Xuben HOU
Acta Pharmaceutica Sinica B 2023;13(6):2425-2463
Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and progression. As promising anticancer targets, HDACs have gained a great deal of research interests and two decades of effort has led to the approval of five HDAC inhibitors (HDACis). However, currently traditional HDACis, although effective in approved indications, exhibit severe off-target toxicities and low sensitivities against solid tumors, which have urged the development of next-generation of HDACi. This review investigates the biological functions of HDACs, the roles of HDACs in oncogenesis, the structural features of different HDAC isoforms, isoform-selective inhibitors, combination therapies, multitarget agents and HDAC PROTACs. We hope these data could inspire readers with new ideas to develop novel HDACi with good isoform selectivity, efficient anticancer effect, attenuated adverse effect and reduced drug resistance.